Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|January 25, 2021

Coronasomnia

Author(s)Thomas So, PharmD

The stress and anxiety of the COVID-19 pandemic might be interfering with sleep patterns.

Thomas So, PharmD, discusses getting a better night's sleep, even during the pandemic.

Dr So is Manager at the Meducation Group at First Databank (FDB).

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Andrey Popov/Adobe Stock

FDA Approves Oveporexton for Narcolepsy Type 1, First Drug to Treat Full Range of NT1 Symptoms

ByJessica Walters

August 5th 2026

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

TNX-102 SL in Major Depressive Disorder: Targeting Slow-Wave Sleep

ByGregory Sullivan, MD

July 29th 2026

Alzheimer

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

ByLeah Kuntz,Tri Doan, MD, PhD

July 20th 2026

cataplexy

FDA Accepts NDA for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15th 2026

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

What Clinicians Might Miss in ADHD: Sleep Disorders, Comorbidities, and a Link to Depression

ByAnn Childress, MD

July 11th 2026

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Feedback Paves Way for New IND Filing for PT00114 in Generalized Anxiety Disorder

A Practical Role for Long-Acting Buprenorphine in Opioid Use Disorder Care

Kratom Component in Clinical Trial for Opioid Use Disorder

Psyched Perspectives: ADHD in Underrecognized Populations, With Paige Walton, MD

Objective Measurement for Psychiatry: Universal Brain's ERP System